Dutch AI Startup Raises €2.3 Million to Predict Surgical Infections Before They Happen
Netherlands, Friday, 26 December 2025.
Healthplus.ai’s breakthrough PERISCOPE® system can save hospitals up to €4 million annually by predicting patient-specific infection risks after surgery and providing targeted prevention actions for medical teams.
Healthcare Innovation Category and Market Impact
This development represents a significant advancement in healthtech, specifically in the medical technology sector where artificial intelligence intersects with surgical care [1]. The Netherlands-based company Healthplus.ai has positioned itself at the forefront of preventive healthcare technology, addressing one of the most costly and dangerous aspects of surgical procedures: post-operative infections [1]. The company’s PERISCOPE® system targets postoperative complications, which represent a major cost center and source of workload pressure in hospitals, with the potential to save individual hospitals up to €4 million annually [1]. This innovation falls squarely within the healthtech category, representing the growing trend of AI-powered predictive medicine that aims to prevent medical complications before they occur rather than treating them after the fact [GPT].
Funding Round Details and Investor Composition
The €2.3 million funding round was completed in late December 2025, with the investment led by Elevating Capital and LUMO Labs [1][3][4]. The round attracted participation from several notable investors including Pathena Venture Capital, Leistone (Renza Family), and ROM InWest [1][3][4]. This late seed-stage investment will enable Healthplus.ai to accelerate the rollout of its PERISCOPE® system across European markets and begin expansion into the United States [1]. Sara Schaafsma, Investment Manager at ROM InWest, emphasized the significance of the investment, stating that accurate patient stratification allows doctors and nurses to create better treatment plans, intervene faster with high-risk patients, and safely discharge low-risk patients earlier [1]. The funding represents part of a broader trend in European healthtech investment, which grew by 52% year-over-year in the first half of 2025, totaling approximately $3.4 billion across 182 deals [4].
How PERISCOPE® Technology Works
The PERISCOPE® system operates by predicting patient-specific infection risks following surgical procedures and directly linking these predictions to targeted actions for healthcare teams [1]. The AI technology integrates seamlessly with Electronic Patient Record (EPD) systems that serve the Dutch and broader European markets, including Epic, Oracle Cerner, and ChipSoft [1]. The system features automatic calibration capabilities, ensuring that predictions remain accurate across different types of hospitals while maintaining compliance with all relevant regulations [1]. Dr. Bart Geerts, CEO and founder of Healthplus.ai, explained that the late seed investment strengthens the company’s ability to integrate clinically validated, regulatory-approved AI into daily hospital practice [1]. The technology focuses on close collaboration with surgical specialists, nurses, and IT teams to ensure that predictive insights genuinely improve patient outcomes [1].
Company Leadership and Geographic Foundation
Healthplus.ai was founded and is led by Dr. Bart Geerts, who serves as both CEO and founder of the company [1]. The company is based in the Netherlands, specifically positioned as part of North Holland’s impressive Life Sciences & Health and AI ecosystem [1]. According to ROM InWest, the region hosts research institutions, educational programs, campuses, startups, hospitals, and investors of the highest caliber, creating an internationally competitive ecosystem [1]. The company exemplifies North Holland’s innovation capabilities by combining AI expertise—where Amsterdam is considered a European leader—with clinical innovation in healthcare [1]. As a MedTech scale-up, Healthplus.ai represents the convergence of world-class AI and Life Sciences & Health sectors, positioning the region for international breakthrough in healthcare technology [1]. The investment connects ROM InWest’s capital and network to a North Holland-based scale-up that demonstrates the region’s capacity to produce globally competitive healthcare innovations [1].